Recent Articles

• 
  Global Business

  K-Bio Wave Hinges on Clinical Validation

  “The country that global pharmaceutical companies should pay closest attention to after China is South Korea. However, whether a real ‘K-bio’ wave arrives five years from now depends on what we do.”Lee Sang-hoon, CEO of bispecific antibody specialist ABL Bio (pictured), made these remarks in an on-s

  2026.06.26
• 
  Clinical Trial

  Celltrion Unveils Japan Trial Data, Validates Remsima SC

  Celltrion has reconfirmed the safety and competitiveness of its subcutaneous formulation autoimmune disease treatment Remsima SC with the latest clinical research data. Celltrion announced on the 25th that it will present the latest clinical results for “Remsima SC (ingredient: infliximab)” in Korea

  2026.06.25
• 
  AI Healthcare

  Drugmakers Race for AI in Digital Healthcare

  One of Korea’s “Big 5” hospitals, Samsung Medical Center, operates a smart ward system. In wards equipped with Daewoong Pharmaceutical’s smart bed monitoring system “THINK,” a palm-sized wearable sensor attached to the inpatient’s chest records biometric signals such as electrocardiogram, body tempe

  2026.06.25
• 
  Global Business

  First Korea Rising Session at BIO USA Signals Asia Innovation Hub

  Korea Rising session The world’s largest pharmaceutical and biotech exhibition, the “2026 BIO International Convention (BIO USA),” hosted an official session dedicated exclusively to highlighting “K-Bio.” The session assessed that the Korean bioindustry is emerging as an “Asian innovation hub” attra

  2026.06.24
• 
  Medical / Research

  ‘Waistline Down 11.6cm’: Wegovy Study in East Asians

  Studies have reported that East Asians, including Koreans, have a relatively high risk of metabolic diseases because they tend to have a higher proportion of abdominal visceral fat even when their body mass index (BMI) is within the normal range. Getty Images Bank There are many Koreans who receive

  2026.06.24
• 
  AI Healthcare

  Daewoong Pharma Installs AI Monitoring at Two National University Hospitals

  ■ Daewoong Pharmaceutical installs ‘AI monitoring system’ in two national university hospitals Daewoong Pharmaceutical announced that it has completed the installation of the artificial intelligence (AI)-based smart bed monitoring system ‘thynC’ at Chonnam National University Hospital and Chonnam Na

  2026.06.24
• 
  Public Health

  New Cardiac Arrest Treatment Standard Includes Recovery, Rehab

  The “2025 Korean Cardiopulmonary Resuscitation (CPR) Guidelines,” which set the national standard for the treatment of cardiac arrest patients, were recently released. Revised for the first time in five years, the new guidelines go beyond the previous CPR- and defibrillation-centered approach and ex

  2026.06.24
• 
  Global Business

  K-Bio Fills China Gap With AI Innovations

  On the 22nd (local time), at the opening of “BIO USA 2026” in San Diego, California, U.S., numerous Korean buyer companies also took part. James Choi, Executive Vice President of Samsung Biologics, introduces the company’s booth. San Diego = Reporter Jeon Hye-jin sunrise@donga.com The “BIO Internati

  2026.06.24
• 
  Bioprocessing / CDMO

  Lotte Bio Wins Approval for Songdo Plant 1

  Lotte Biologics announced on the 22nd that it has completed construction of the main facilities at Plant 1 of its Incheon Songdo Bio Campus and obtained approval for use. The plant has the capacity to produce a total of 120,000 L of antibody therapeutics. “Approval for use” means that not only the b

  2026.06.23
• 
  DTx / Platform

  IlDong NewroMS Chosen for Remote Island Doctor Program

  Ildong Pharmaceutical Group’s Saerom MS is installing and operating Saero Doctor, a remote medical treatment kiosk device, to help resolve medical blind spots. Provided by Saerom MS. Ildong Pharmaceutical Group announced on the 22nd that its healthcare platform subsidiary Saerom MS has been selected

  2026.06.22